详情页 - 河北大学附属医院知识库

资源类型：

文章类型：

作者：

Li, Jian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] * ; Xu, Ye[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zang, Aimin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Gao, Yunong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Gao, Quanli[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Yanqiao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Dong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Xu, Jianming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Yuan, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Jiang, Haiping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ying, Jieer[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Shi, Chunmei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Deng, Yanhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Jing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Liu, Tianshu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Huang, Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Xu, Yaling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Yidi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Fei, Cong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Shen, Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ;

机构： [1]Beijing Cancer Hospital, Beijing, China [2]Fudan University Shanghai Cancer Center, Shanghai, China [3]Affiliated Hospital of Hebei University, Hebei, China [4]Henan Cancer Hospital, Henan, China [5]Harbin Medical University Cancer Hospital, Harbin, China [6]Chongqing Cancer Hospital, Chongqing, China [7]The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China [8]The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China [9]The First Affiliated Hospital of Medical School of Zhejiang University, Zhejiang, China [10]Zhejiang Cancer Hospital, Beijing, China [11]Fujian Medical University Union Hopsital, Fujian, China [12]The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [13]Hunan Cancer Hospital, Hunan, China [14]Zhongshan Hospital of Fudan University, Shanghai, China [15]Hubei Cancer Hospital, Hubei, China [16]BeiGene (Shanghai) Co., Ltd., Shanghai, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Beijing Cancer Hospital, Beijing, China [2]Fudan University Shanghai Cancer Center, Shanghai, China [3]Affiliated Hospital of Hebei University, Hebei, China [4]Henan Cancer Hospital, Henan, China [5]Harbin Medical University Cancer Hospital, Harbin, China [6]Chongqing Cancer Hospital, Chongqing, China [7]The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China [8]The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China [9]The First Affiliated Hospital of Medical School of Zhejiang University, Zhejiang, China [10]Zhejiang Cancer Hospital, Beijing, China [11]Fujian Medical University Union Hopsital, Fujian, China [12]The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [13]Hunan Cancer Hospital, Hunan, China [14]Zhongshan Hospital of Fudan University, Shanghai, China [15]Hubei Cancer Hospital, Hubei, China [16]BeiGene (Shanghai) Co., Ltd., Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors

文献详情